CMHC Masterclass On Demand: Addressing the NAFLD / NASH Epidemic: Advances in Pathophysiology, Diagnosis and Management

The increasing rates of obesity, diabetes, and metabolic syndrome in the United States are leading to more cases NAFLD and NASH, which are now being encountered at a greater frequency in clinical practice. NASH can lead to significant morbidity and mortality, including liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC)—in fact, HCC caused by NASH is poised to become the leading cause of liver transplants in the US.

Significant advances have been made in the understanding of NAFLD/NASH pathophysiology, risk factors, and disease progression, leading to newer diagnostic approaches and therapeutic targets. However, navigating these developments is no easy feat--for example, there are now more than 150 clinical trials for NASH. Are we getting closer to a treatment? What does the future look like? What can we do now to treat NASH? Who is responsible for screening and diagnosing?

During this engaging CMHC Masterclass meeting, you will have a chance to hear from and interact with experts in the NASH space across all specialties. The meeting is designed to bring forward cutting-edge perspectives to the diagnosis and management of NAFLD/NASH, as well as highlight multi-disciplinary solutions that are ultimately needed to improve outcomes.

Target Audience

The Cardiometabolic Health Congress (CMHC) is designed for US-based healthcare professionals, including endocrinologists, diabetologists, hepatologists, and gastroenterologists as well as registered nurses, nurse practitioners, pharmacists, and dieticians.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Review NAFLD/NASH pathogenesis, disease progression, and risk factors for disease progression in order to improve the identification of NASH
  • Define current and emerging approaches and tools to diagnose NAFLD and NASH in clinical practice
  • Utilize the current guidelines and recommendations for treatment of NAFLD and NASH in order to optimize patient management
  • List emerging NASH pharmacotherapies that aim to target various metabolic, inflammatory, and fibrotic pathways involved in disease progression.
Course summary
Available credit: 
  • 5.50 ACPE Pharmacy
  • 5.50 AMA PRA Category 1 Credit™
  • 5.50 ANCC
  • 5.50 CDE
  • 5.50 Participation
Course opens: 
04/05/2021
Course expires: 
04/05/2022
Rating: 
0

Christos S. Mantzoros, MD, DSC
Professor of Medicine
Harvard Medical School
Adjunct Professor
Boston University School of Medicine

Stephen A. Harrison, MD, FACP, FAASLD, COL (ret.), USA
Medical Director
Pinnacle Clinical Research
San Antonio, TX

Kenneth Cusi, MD, FACP, FACE
Professor of Medicine
University of Florida
Gainesville, FL

Fasiha Kanwal, MD, MSHS, AGAF, FAASLD
Professor and Chief
Baylor College of Medicine
Houston, TX

Amreen M Dinani, MD
Assistant Professor of Medicine
Division of Liver Diseases
Mount Sinai Health System
New York, NY

Rohit Loomba, MD
Professor of Medicine
University of California
San Diego, CA

 

 

ESTIMATED TIME TO COMPLETE ACTIVITY
5.5 hours

JOINT ACCREDITATION STATEMENT
image   image   image



In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 5.5 AMA PRA Category 1 Credits™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 5.5 contact hours. Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate. 

CONTINUING PHARMACY EDUCATION
Postgraduate Institute for Medicine designates this continuing education activity for 5.5  contact hour(s) (.55 CEUs) of the Accreditation Council for Pharmacy Education.

This is an application-based activity. Universal Activity Numbers (UAN): # JA4008162-9999-21-2671-H01-P

For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.

CONTINUING DIETICIAN EDUCATION
This program offers 5.5 CPEUs for dieticians.

DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty
A full listing of faculty disclosures PDF icon can be downloaded here

Planners and Managers
The PIM planners and managers have nothing to disclose. The CMHC planners and managers have nothing to disclose.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management.  Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

METHOD OF PARTICIPATION & REQUEST FOR CREDIT
There are no registration fees for this activity. During the period April 5, 2021 through April 5, 2022, participants must read the learning objectives and faculty disclosures, study the educational activity, obtain a score of 75% or better on the post-test, and complete the evaluation. Upon completing, your certificate will be available for print. For questions about receiving certificates, please contact us at CMHC_Eval@cardiometabolichealth.org.

For questions about the accreditation of this activity, please visit www.pimed.com.

For Pharmacists: Please complete the evaluation instructions above. Upon registering and completing the activity evaluation, your transcript information will be sent to the NABP CPE Monitor Service within 4-6 weeks.

Available Credit

  • 5.50 ACPE Pharmacy
  • 5.50 AMA PRA Category 1 Credit™
  • 5.50 ANCC
  • 5.50 CDE
  • 5.50 Participation
Please login or register to take this course.

There are no registration fees for this activity. Please enroll and proceed with the course instructions.

Required Hardware/software

A computer with an internet connection

Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser

Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.